What P-Glycoprotein (MDR1) Actually Does
P-glycoprotein is a bouncer working the door of your cells: it spots foreign substances—including a lot of common medications—and pumps them right back out before they can build up inside. That’s the whole gig. It sits in cell membranes and shoves drugs out the way a bouncer escorts uninvited guests off the premises.
Why should you care? Because that pumping action can throw a drug out before it has a chance to work, or, when the pump is blocked, let a drug pile up to levels that cause surprise side effects. Either way, P-gp can quietly decide whether your medication helps or harms.
Location explains everything. P-gp is concentrated in your gut lining (where it limits how much of a pill you absorb), the blood-brain barrier (keeping substances out of your brain), and your kidneys and liver (helping flush drugs from the body). Those checkpoints are why this one protein has such outsized influence.
You’ve probably landed here for one of three reasons, and this article addresses each:
- Everyday drug and food interactions—why a combination might backfire
- Cancer multidrug resistance—why a treatment stopped working
- Canine MDR1 sensitivity—what a herding dog’s genetic test result means
One last name note: P-gp, MDR1, and ABCB1 are all the same thing.
P-gp, MDR1, ABCB1: Why One Thing Has Three Names
The good news before you read another paragraph: P-gp, MDR1, and ABCB1 are not three different things to untangle. They’re three names for the same biological pump, born at different moments in scientific history.
P-glycoprotein (P-gp) is the name for the protein itself—the molecular “bouncer” in your cell membranes. MDR1 is the older name for the gene that codes for that protein. ABCB1 is the current official gene name, assigned by the HUGO Gene Nomenclature Committee. Same system, three labels.
Which one you’ll run into depends on where you’re looking:
- Drug labels and pharmacist notes: usually “P-gp” (e.g., “this drug is a P-gp inhibitor”)
- Human genetic tests and research papers: often “ABCB1,” sometimes “MDR1”
- Vet reports for dogs: almost always “MDR1” (canine genetics kept the older name)
One more reassurance: the “multidrug resistance” buried in MDR1 does not mean cancer is involved. That phrase describes how broadly this pump pushes substances out of cells—a wide reach, not a diagnosis. You don’t need to memorize any of this; recognize that all three terms point to the same pump.
How P-gp Affects Everyday Drug and Food Interactions
Here’s where P-gp stops being abstract biochemistry and starts affecting whether your morning pill does its job. Think of three roles in this story. Substrates are the drugs P-gp grabs and pumps back out before they’re fully absorbed—the bouncer’s targets. Inhibitors jam the bouncer, so substrates flood in and drug levels climb higher than your doctor intended. Inducers do the opposite: they recruit more bouncers, so a drug gets shoved out faster and may quietly underperform.
The practical danger lives in the combinations. Pair an inhibitor with a substrate, and you can get a surprise spike—suddenly your “normal” dose behaves like an overdose. Pair an inducer with a substrate, and a medication you’re counting on may stop working without any obvious warning sign.
Common substrates worth knowing include digoxin (a heart medication), certain statins, some chemotherapy agents, and anti-arrhythmics. Common inhibitors include verapamil (a blood pressure drug), several antifungals like ketoconazole, and some antibiotics such as clarithromycin.
The food and supplement angle
Two everyday culprits deserve a flag. Grapefruit (and its juice) inhibits P-gp and related enzymes, nudging drug levels up. St. John’s Wort, a popular over-the-counter mood supplement, is a potent inducer that can sabotage everything from birth control to transplant drugs.
If you take multiple medications, ask your pharmacist directly: “Do any of these interact through P-glycoprotein?” It’s a question they’re equipped to answer fast.
P-glycoprotein and Cancer Multidrug Resistance
Remember that cellular bouncer? Cancer cells can hire a whole army of them. When a tumor is bombarded with chemotherapy, some cells survive by cranking up production of P-glycoprotein, studding their surface with pumps that shove the drug back out before it can do damage. The chemo arrives, but the cell ejects it like an unwanted guest.
This is why a regimen that worked beautifully for months can quietly lose its grip. The drug hasn’t changed—the cancer has learned to spit it out. Worse, because P-gp recognizes a broad range of compounds, resistance to one drug can spill over into resistance to several others at once. That’s the “multidrug” in multidrug resistance.
Oncologists have several moves here. They may switch to drugs P-gp ignores, combine agents, or change the delivery approach. Researchers spent years testing P-gp inhibitor drugs to block the pumps directly, but these proved frustrating in trials—they often caused toxicity or interfered with healthy tissues that rely on P-gp, so none became a routine fix.
Here’s the part worth holding onto: P-gp is one resistance mechanism among many, and resistance is not a dead end. New regimens, targeted therapies, and immunotherapies sidestep this problem entirely. If you’ve heard the words “multidrug resistance,” that’s a conversation to have with your oncology team—not a verdict.
MDR1 Sensitivity in Dogs: Decoding the Test Result
If your herding dog got flagged for MDR1 sensitivity, here’s the reassuring headline: this is a known, manageable genetic quirk—not a death sentence. The phrase you’ll see on the printout is “MDR1 mutation” (also written ABCB1), and it’s especially common in Collies, Australian Shepherds, Shelties, Old English Sheepdogs, and Long-haired Whippets. Roughly 3 in 4 Collies carry at least one copy.
Normally, P-glycoprotein acts as a bouncer at the blood-brain barrier, pumping certain drugs back out before they reach your dog’s brain. The mutation breaks that pump. Without it working, drugs that should stay out—ivermectin (and some other dewormers at high doses), loperamide (Imodium), certain chemotherapy agents, and some sedatives like acepromazine—can accumulate and cause neurological toxicity: tremors, disorientation, seizures, even coma.
Reading your result
- Normal/Normal: Two working copies. Standard dosing is fine.
- Mutant/Normal (carrier): One working copy. Partial risk—often needs dose reductions for sensitive drugs.
- Mutant/Mutant: No working copies. High risk—those drugs should generally be avoided or dosed very cautiously.
Washington State University’s veterinary lab pioneered this test and maintains a current drug list worth bookmarking. The practical move: tell every vet your dog’s MDR1 status before any new prescription, sedation, or surgery, and ask whether the planned drug is a P-gp substrate. With that one habit, a positive result becomes a footnote, not a crisis.
Red Flags: Signs P-gp May Be Affecting Your Medication
The clue is almost always in the timing. If a side effect or a sudden drop in how well a drug works shows up right after you change something, P-gp deserves a look as the hidden culprit.
Signs your drug levels may be climbing too high: new or worsening side effects—dizziness, nausea, unusual fatigue, a racing heart—that appear within days of adding a second medication, a supplement (St. John’s wort and milk thistle are common offenders), or even a daily habit like grapefruit juice. When a P-gp inhibitor blocks the pump, more drug stays in your system than intended.
Signs your levels may be dropping too low: a medication that reliably worked for months suddenly underperforming—seizures breaking through, pain returning, blood pressure creeping up—often after starting something that revs the pump up.
The pattern that should make you pause: symptoms that line up with a recent medication, diet, or supplement change. That correlation is worth raising with your doctor or pharmacist.
For dogs
In herding breeds especially, watch for lethargy, disorientation, drooling, tremors, or wobbliness after a new medication. These are red flags for neurological toxicity—call your vet promptly.
One firm rule: never stop or adjust a prescription on your own based on suspicion alone. Abrupt changes can be more dangerous than the interaction. Flag it, then let a professional adjust the plan.
What to Ask Your Doctor, Pharmacist, or Vet
The fastest way to turn this knowledge into a decision is to ask the right person the right question—and that person is usually your pharmacist. Unlike a doctor’s appointment, a pharmacist consultation is free, walk-in, and often available the same day. According to Consumer Reports, pharmacists routinely catch interactions that slip past busy prescribers, and P-gp conflicts are squarely in their wheelhouse.
Before any of these conversations, bring a complete list—prescriptions, over-the-counter drugs, supplements, and even regular foods like grapefruit. Then ask:
For your pharmacist
- “Do any of my medications interact through P-glycoprotein?”
- “Is it safe to combine these with grapefruit, St. John’s wort, or my supplements?”
For your doctor
- “Could a P-gp interaction explain these side effects, or why this drug doesn’t seem to be working?”
- “Should we adjust the dose or timing instead of switching drugs entirely?”
For your vet
- “Given my dog’s breed, should we run an MDR1 test before prescribing anything?”
- “Which drugs should we avoid or dose-reduce based on the result?”
An MDR1 cheek-swab test typically runs $60–$80 and is worth it for herding breeds. Whatever your situation, you don’t need to diagnose the interaction yourself—name P-glycoprotein and let the expert do the cross-check.
Key Takeaways: Putting P-glycoprotein in Perspective
Strip away the biochemistry, and P-glycoprotein comes down to a single image: a cellular bouncer that pumps certain molecules back out before they can build up inside your cells. That one job shows up in three places that matter to real life—everyday drug and food interactions, cancer multidrug resistance, and canine MDR1 sensitivity—but it’s always the same pump doing the same thing.
The most useful thing to remember is that P-gp isn’t a disease or a defect. It’s a normal, protective system that’s been guarding your gut, brain, and kidneys long before you ever read the term on a label. The trouble starts only when a second drug, a food like grapefruit, or a genetic variant changes how hard that bouncer works.
So the actionable move is never to self-adjust doses—it’s to verify interactions with a pharmacist, doctor, or vet who can check the specific combination. Bring the names of everything you’re taking and ask directly. Interactions are manageable once they’re flagged, cancer resistance is one factor among many your oncology team weighs, and MDR1-positive dogs live full, normal lives with the right drug precautions noted in their chart.
